This study solidifies the role of SCN5A mutations as not only a diagnostic marker but also a prognostic biomarker, useful for risk stratification and predicting the recurrence of ventricular arrhythmias in BrS patients [20]. This evidence concerns the gene SCN5A and Ventricular arrhythmia.